{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T03:36:05Z","timestamp":1774668965370,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guangzhou Science and Technology Project","award":["202201020453"],"award-info":[{"award-number":["202201020453"]}]},{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2021A1515110818"],"award-info":[{"award-number":["2021A1515110818"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-04286-z","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T14:48:28Z","timestamp":1759157308000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment of patients with hyperthyroidism and liver failure: a retrospective cohort study"],"prefix":"10.1186","volume":"25","author":[{"given":"Zhanyi","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqiong","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinyao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuankai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"4286_CR1","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/S0140-6736(16)00278-6","volume":"388","author":"S De Leo","year":"2016","unstructured":"De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016;388:906\u201318. https:\/\/doi.org\/10.1016\/S0140-6736(16)00278-6.","journal-title":"Lancet"},{"key":"4286_CR2","first-page":"337","volume":"7","author":"S Khemichian","year":"2011","unstructured":"Khemichian S, Fong TL. Hepatic dysfunction in hyperthyroidism. Gastroenterol Hepatol (N Y). 2011;7:337\u20139.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"4286_CR3","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S1089-3261(02)00049-1","volume":"6","author":"WI Youssef","year":"2002","unstructured":"Youssef WI, Mullen KD. The liver in other (nondiabetic) endocrine disorders. Clin Liver Dis. 2002;6:879\u201389. https:\/\/doi.org\/10.1016\/S1089-3261(02)00049-1.","journal-title":"Clin Liver Dis"},{"key":"4286_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/CEG.S39358","volume":"6","author":"DF de Campos Mazo","year":"2013","unstructured":"de Campos Mazo DF, de Vasconcelos GB, Pereira MA, de Mello ES, Bacchella T, Carrilho FJ, et al. Clinical spectrum and therapeutic approach to hepatocellular injury in patients with hyperthyroidism. Clin Exp Gastroenterol. 2013;6:9\u201317. https:\/\/doi.org\/10.2147\/CEG.S39358.","journal-title":"Clin Exp Gastroenterol"},{"issue":"25","key":"4286_CR5","doi-asserted-by":"publisher","first-page":"8102","DOI":"10.3748\/wjg.v20.i25.8102","volume":"20","author":"A Eshraghian","year":"2014","unstructured":"Eshraghian A, Hamidian Jahromi A. Non-alcoholic fatty liver disease and thyroid dysfunction: a systematic review. World J Gastroenterol. 2014;20(25):8102\u20139. https:\/\/doi.org\/10.3748\/wjg.v20.i25.8102.","journal-title":"World J Gastroenterol"},{"key":"4286_CR6","doi-asserted-by":"publisher","first-page":"117955142210746","DOI":"10.1177\/11795514221074672","volume":"15","author":"E Yorke","year":"2022","unstructured":"Yorke E. Hyperthyroidism and liver dysfunction: a review of a common comorbidity. Clin Med Insights Endocrinol Diabetes. 2022;15:11795514221074672. https:\/\/doi.org\/10.1177\/11795514221074672.","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"issue":"4","key":"4286_CR7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2169\/internalmedicine.42.331","volume":"42","author":"B Cui","year":"2003","unstructured":"Cui B, Abe M, Hidata S, Nakanishi S, Matsuura B, Michitaka K, et al. Autoimmune hepatitis associated with graves\u2019 disease. Intern Med. 2003;42(4):331\u20135. https:\/\/doi.org\/10.2169\/internalmedicine.42.331.","journal-title":"Intern Med"},{"issue":"1","key":"4286_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1124\/dmd.107.018184","volume":"36","author":"Y Kato","year":"2008","unstructured":"Kato Y, Ikushiro S, Emi Y, Tamaki S, Suzuki H, Sakaki T, et al. Hepatic UDP-glucuronosyltransferases responsible for glucuronidation of thyroxine in humans. Drug Metab Dispos. 2008;36(1):51\u20135. https:\/\/doi.org\/10.1124\/dmd.107.018184.","journal-title":"Drug Metab Dispos"},{"key":"4286_CR9","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/thy.2016.0229","volume":"26","author":"DS Ross","year":"2016","unstructured":"Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26:1343\u2013421. https:\/\/doi.org\/10.1089\/thy.2016.0229.","journal-title":"Thyroid"},{"key":"4286_CR10","doi-asserted-by":"publisher","first-page":"BP27","DOI":"10.1007\/s00259-002-1062-4","volume":"30","author":"EANM","year":"2003","unstructured":"EANM. EANM procedure guidelines for therapy with iodine-131. Eur J Nucl Med Mol Imaging. 2003;30:BP27\u201331. https:\/\/doi.org\/10.1007\/s00259-002-1062-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4286_CR11","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/qjmed\/95.9.559","volume":"95","author":"R Malik","year":"2002","unstructured":"Malik R, Hodgson H. The relationship between the thyroid gland and the liver. QJM. 2002;95:559\u201369. https:\/\/doi.org\/10.1093\/qjmed\/95.9.559.","journal-title":"QJM"},{"key":"4286_CR12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.4158\/EP161417.OR","volume":"23","author":"Q Zhang","year":"2017","unstructured":"Zhang Q, Guan Y, Xiang T, Liu S, Chen Q, Zhang Q. Combination of molecular adsorbent recirculating system and radioiodine for the treatment of concurrent hyperthyroidism and severe liver dysfunction: a retrospective cohort study. Endocr Pract. 2017;23:141\u20138. https:\/\/doi.org\/10.4158\/EP161417.OR.","journal-title":"Endocr Pract"},{"key":"4286_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1034374","volume":"13","author":"M Rao","year":"2022","unstructured":"Rao M, Wang Y, Ren J, Chen Y, Zheng C, Xiong Y, et al. Effect of 131I with and without artificial liver support system in patients with Graves\u2019 disease and severe liver dysfunction: A retrospective study. Front Endocrinol (Lausanne). 2022;13:1034374. https:\/\/doi.org\/10.3389\/fendo.2022.1034374.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4286_CR14","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1002\/hep.31316","volume":"72","author":"R Hernaez","year":"2020","unstructured":"Hernaez R, Patel A, Jackson LK, Braun UK, Walling AM, Rosen HR. Considerations for prognosis, goals of care, and specialty palliative care for hospitalized patients with acute-on-chronic liver failure. Hepatology. 2020;72:1109\u201316. https:\/\/doi.org\/10.1002\/hep.31316.","journal-title":"Hepatology"},{"key":"4286_CR15","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1111\/liv.14328","volume":"40","author":"N Mahmud","year":"2020","unstructured":"Mahmud N, Hubbard RA, Kaplan DE, Taddei TH, Goldberg DS. Risk prediction scores for acute on chronic liver failure development and mortality. Liver Int. 2020;40:1159\u201367. https:\/\/doi.org\/10.1111\/liv.14328.","journal-title":"Liver Int"},{"key":"4286_CR16","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1056\/NEJMra1914900","volume":"382","author":"V Arroyo","year":"2020","unstructured":"Arroyo V, Moreau R, Jalan R. Acute-on-chronic liver failure. N Engl J Med. 2020;382:2137\u201345. https:\/\/doi.org\/10.1056\/NEJMra1914900.","journal-title":"N Engl J Med"},{"key":"4286_CR17","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1210\/jc.2009-2752","volume":"95","author":"AB Emiliano","year":"2010","unstructured":"Emiliano AB, Governale L, Parks M, Cooper DS. Shifts in propylthiouracil and methimazole prescribing practices: antithyroid drug use in the united States from 1991 to 2008. J Clin Endocrinol Metab. 2010;95:2227\u201333. https:\/\/doi.org\/10.1210\/jc.2009-2752.","journal-title":"J Clin Endocrinol Metab"},{"key":"4286_CR18","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1089\/thy.2016.0222","volume":"26","author":"JP Brito","year":"2016","unstructured":"Brito JP, Schilz S, Singh Ospina N, Rodriguez-Gutierrez R, Maraka S, Sangaralingham LR, et al. Antithyroid drugs\u2014the most common treatment for Graves\u2019 disease in the United States: a nationwide population-based study. Thyroid. 2016;26:1144\u20135. https:\/\/doi.org\/10.1089\/thy.2016.0222.","journal-title":"Thyroid"},{"key":"4286_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000490384","volume":"7","author":"GJ Kahaly","year":"2018","unstructured":"Kahaly GJ, Bartalena L, Heged\u00fcs L, Leenhardt L, Poppe K, Pearce SH. 2018 European thyroid association guideline for the management of graves\u2019 hyperthyroidism. Eur Thyroid J. 2018;7:167\u201386. https:\/\/doi.org\/10.1159\/000490384.","journal-title":"Eur Thyroid J"},{"key":"4286_CR20","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1007\/s12072-019-09980-1","volume":"13","author":"SK Sarin","year":"2019","unstructured":"Sarin SK, Choudhury A, Sharma MK, Maiwall R, Al Mahtab M, Rahman S, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019;13:826\u20138. https:\/\/doi.org\/10.1007\/s12072-019-09980-1.","journal-title":"Hepatol Int"},{"issue":"4","key":"4286_CR21","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s12072-024-10697-z","volume":"18","author":"X Xu","year":"2024","unstructured":"Xu X, Ding H, Jia J, Wei L, Duan Z, Tang C, et al. Chinese guidelines on the management of ascites in cirrhosis: Chinese society of hepatology, Chinese medical association. Hepatol Int. 2024;18(4):1071\u201389. https:\/\/doi.org\/10.1007\/s12072-024-10697-z.","journal-title":"Hepatol Int"},{"issue":"3","key":"4286_CR22","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jhep.2022.06.001","volume":"77","author":"European Association for the Study of the Liver","year":"2022","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatic encephalopathy. J Hepatol. 2022;77(3):807\u201324. https:\/\/doi.org\/10.1016\/j.jhep.2022.06.001.","journal-title":"J Hepatol"},{"issue":"12","key":"4286_CR23","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1080\/00365521.2023.2244107","volume":"58","author":"C Li","year":"2023","unstructured":"Li C, Wang KL, Hu JH, Su HB. Clinical manifestations and early effectiveness of methimazole in patients with graves\u2019 hyperthyroidism-related severe hepatic dysfunction. Scand J Gastroenterol. 2023;58(12):1514\u201322. https:\/\/doi.org\/10.1080\/00365521.2023.2244107.","journal-title":"Scand J Gastroenterol"},{"key":"4286_CR24","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/clpt.2011.58","volume":"89","author":"GP Aithal","year":"2011","unstructured":"Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89:806\u201315. https:\/\/doi.org\/10.1038\/clpt.2011.58.","journal-title":"Clin Pharmacol Ther"},{"key":"4286_CR25","doi-asserted-by":"publisher","DOI":"10.56759\/ojsg8296","volume-title":"Drug-induced liver injury (DILI): current status and future directions for drug development and the post-market setting","author":"Council for International Organizations of Medical Sciences (CIOMS)","year":"2020","unstructured":"Council for International Organizations of Medical Sciences (CIOMS). Drug-induced liver injury (DILI): current status and future directions for drug development and the post-market setting. Geneva, Switzerland: CIOMS; 2020. https:\/\/doi.org\/10.56759\/ojsg8296."},{"key":"4286_CR26","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","volume":"70","author":"European Association for the Study of the Liver","year":"2019","unstructured":"European Association for the Study of the Liver, Clinical Practice Guideline Panel. EASL clinical practice guidelines: drug-induced liver injury. J Hepatol. 2019;70:1222\u201361. https:\/\/doi.org\/10.1016\/j.jhep.2019.02.014.","journal-title":"J Hepatol"},{"key":"4286_CR27","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/hep.32689","volume":"77","author":"RJ Fontana","year":"2023","unstructured":"Fontana RJ, Liou I, Reuben A, Suzuki A, Fiel MI, Lee W, et al. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology. 2023;77:1036\u201365. https:\/\/doi.org\/10.1002\/hep.32689.","journal-title":"Hepatology"},{"key":"4286_CR28","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1097\/HEP.0000000000000671","volume":"79","author":"CJ Karvellas","year":"2024","unstructured":"Karvellas CJ, Bajaj JS, Kamath PS, Napolitano L, O\u2019Leary JG, Sol\u00e0 E, et al. Aasld practice guidance on acute-on-chronic liver failure and the management of critically ill patients with cirrhosis. Hepatology. 2024;79:1463\u2013502. https:\/\/doi.org\/10.1097\/HEP.0000000000000671.","journal-title":"Hepatology"},{"key":"4286_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1478-3231.2012.02790.x","volume":"33","author":"KA Wlodzimirow","year":"2013","unstructured":"Wlodzimirow KA, Eslami S, Abu-Hanna A, Nieuwoudt M, Chamuleau RA. A systematic review on prognostic indicators of acute-on-chronic liver failure and their predictive value for mortality. Liver Int. 2013;33:40\u201352. https:\/\/doi.org\/10.1111\/j.1478-3231.2012.02790.x.","journal-title":"Liver Int"},{"issue":"3","key":"4286_CR30","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1177\/1535370215602784","volume":"241","author":"Y Ding","year":"2016","unstructured":"Ding Y, Xing J, Fang Y, Wang Y, Zhang Y, Long Y. 131I therapy for 345 patients with refractory severe hyperthyroidism: Without antithyroid drug pretreatment. Exp Biol Med (Maywood). 2016;241(3):290\u20135. https:\/\/doi.org\/10.1177\/1535370215602784.","journal-title":"Exp Biol Med (Maywood)"},{"key":"4286_CR31","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1053\/jhep.2001.22172","volume":"33","author":"PS Kamath","year":"2001","unstructured":"Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464\u201370. https:\/\/doi.org\/10.1053\/jhep.2001.22172.","journal-title":"Hepatology"},{"key":"4286_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.779744","volume":"8","author":"YY Chen","year":"2021","unstructured":"Chen YY, Li H, Xu BY, Zheng X, Li BL, Wang XB, et al. Plasma exchange-based non-bioartificial liver support system improves the short-term outcomes of patients with hepatitis B virus-associated acute-on-chronic liver failure: a multicenter prospective cohort study. Front Med. 2021;8:779744. https:\/\/doi.org\/10.3389\/fmed.2021.779744.","journal-title":"Front Med"},{"issue":"4","key":"4286_CR33","doi-asserted-by":"publisher","first-page":"100600","DOI":"10.1016\/j.gastha.2024.100600","volume":"4","author":"XF Zhu","year":"2024","unstructured":"Zhu XF, Ding RR, Wang BY, Yang YH, Ta FX, Wang Y, et al. Iodine-131 combined with plasma exchange treatment in graves\u2019 hyperthyroidism patients with severe liver injury whose average model for End-Stage liver disease scores\u2009>\u200920. Gastro Hep Adv. 2024;4(4):100600. https:\/\/doi.org\/10.1016\/j.gastha.2024.100600.","journal-title":"Gastro Hep Adv"},{"issue":"1","key":"4286_CR34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13613-020-00795-0","volume":"11","author":"K Ocskay","year":"2021","unstructured":"Ocskay K, Kanjo A, Gede N, Szak\u00e1cs Z, P\u00e1r G, Er\u0151ss B, Stange J, et al. Uncertainty in the impact of liver support systems in acute-on-chronic liver failure: a systematic review and network meta-analysis. Ann Intensive Care. 2021;11(1):10. https:\/\/doi.org\/10.1186\/s13613-020-00795-0.","journal-title":"Ann Intensive Care"},{"issue":"10","key":"4286_CR35","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1136\/gutjnl-2017-314240","volume":"67","author":"J Fern\u00e1ndez","year":"2018","unstructured":"Fern\u00e1ndez J, Acevedo J, Wiest R, Gustot T, Amoros A, Deulofeu C, Reverter E, Mart\u00ednez J, Saliba F, Jalan R, Welzel T, Pavesi M, Hern\u00e1ndez-Tejero M, Gin\u00e8s P, Arroyo V, European Foundation for the Study of Chronic Liver Failure. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut. 2018;67(10):1870\u201380. https:\/\/doi.org\/10.1136\/gutjnl-2017-314240.","journal-title":"Gut"},{"issue":"1","key":"4286_CR36","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","volume":"70","author":"SK Asrani","year":"2019","unstructured":"Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151\u201371. https:\/\/doi.org\/10.1016\/j.jhep.2018.09.014.","journal-title":"J Hepatol"},{"issue":"5","key":"4286_CR37","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/hep.28785","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the united States and Europe. Hepatology. 2016;64(5):1577\u201386. https:\/\/doi.org\/10.1002\/hep.28785.","journal-title":"Hepatology"},{"issue":"9","key":"4286_CR38","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1038\/ajg.2011.157","volume":"106","author":"JS Bajaj","year":"2011","unstructured":"Bajaj JS, Wade JB, Gibson DP, Heuman DM, Thacker LR, Sterling RK, et al. The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol. 2011;106(9):1646\u201353. https:\/\/doi.org\/10.1038\/ajg.2011.157.","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"4286_CR39","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMra042972","volume":"352","author":"DS Cooper","year":"2005","unstructured":"Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352(9):905\u201317. https:\/\/doi.org\/10.1056\/NEJMra042972.","journal-title":"N Engl J Med"},{"issue":"11","key":"4286_CR40","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s40618-019-01054-1","volume":"42","author":"F Azizi","year":"2019","unstructured":"Azizi F, Malboosbaf R. Safety of long-term antithyroid drug treatment? A systematic review. J Endocrinol Invest. 2019;42(11):1273\u201383. https:\/\/doi.org\/10.1007\/s40618-019-01054-1.","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"4286_CR41","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/bcp.12336","volume":"78","author":"MT Wang","year":"2014","unstructured":"Wang MT, Lee WJ, Huang TY, Chu CL, Hsieh CH. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study. Br J Clin Pharmacol. 2014;78(3):619\u201329. https:\/\/doi.org\/10.1111\/bcp.12336.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"4286_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5681\/apb.2015.001","volume":"5","author":"R Heidari","year":"2015","unstructured":"Heidari R, Niknahad H, Jamshidzadeh A, Eghbal MA, Abdoli N. An overview on the proposed mechanisms of antithyroid drugs-induced liver injury. Adv Pharm Bull. 2015;5(1):1\u201311. https:\/\/doi.org\/10.5681\/apb.2015.001.","journal-title":"Adv Pharm Bull"},{"key":"4286_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109095","volume":"117","author":"X Li","year":"2019","unstructured":"Li X, Jin S, Fan Y, Fan X, Tang Z, Cai W, et al. Association of HLA-C*03:02 with methimazole-induced liver injury in graves\u2019 disease patients. Biomed Pharmacother. 2019;117:109095. https:\/\/doi.org\/10.1016\/j.biopha.2019.109095.","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"4286_CR44","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/14740338.2018.1502747","volume":"17","author":"LC Chang","year":"2018","unstructured":"Chang LC, Chang CC, Chen PL, Wang SH, Chen YH, Tsai YH, et al. Thyrotropin receptor antibodies and a genetic hint in antithyroid drug-induced adverse drug reactions. Expert Opin Drug Saf. 2018;17(8):775\u201384. https:\/\/doi.org\/10.1080\/14740338.2018.1502747.","journal-title":"Expert Opin Drug Saf"},{"issue":"7","key":"4286_CR45","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1210\/jc.2009-2546","volume":"95","author":"SA Rivkees","year":"2010","unstructured":"Rivkees SA, Szarfman A. Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children. J Clin Endocrinol Metab. 2010;95(7):3260\u20137. https:\/\/doi.org\/10.1210\/jc.2009-2546.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"4286_CR46","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4158\/EP-2019-0221","volume":"26","author":"W Yu","year":"2020","unstructured":"Yu W, Wu N, Li L, Wang J, OuYang H, Shen H. Side effects of PTU and MMI in the treatment of hyperthyroidism: a systematic review and meta-analysis. Endocr Pract. 2020;26(2):207\u201317. https:\/\/doi.org\/10.4158\/EP-2019-0221.","journal-title":"Endocr Pract"},{"issue":"10","key":"4286_CR47","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1089\/thy.2019.0045","volume":"29","author":"N Suzuki","year":"2019","unstructured":"Suzuki N, Noh JY, Hiruma M, Kawaguchi A, Morisaki M, Ohye H, et al. Analysis of antithyroid drug-induced severe liver injury in 18,558 newly diagnosed patients with graves\u2019 disease in Japan. Thyroid. 2019;29(10):1390\u20138. https:\/\/doi.org\/10.1089\/thy.2019.0045.","journal-title":"Thyroid"},{"issue":"8","key":"4286_CR48","doi-asserted-by":"publisher","first-page":"974","DOI":"10.4158\/EP161222.OR","volume":"22","author":"DA Niculescu","year":"2016","unstructured":"Niculescu DA, Dusceac R, Galoiu SA, Capatina CA, Poiana C. Serial changes of liver function tests before and during methimazole treatment in thyrotoxic patients. Endocr Pract. 2016;22(8):974\u20139. https:\/\/doi.org\/10.4158\/EP161222.OR.","journal-title":"Endocr Pract"},{"key":"4286_CR49","doi-asserted-by":"publisher","first-page":"768019","DOI":"10.1155\/2012\/768019","volume":"2012","author":"MO Hegazi","year":"2012","unstructured":"Hegazi MO, Ahmed S. Atypical clinical manifestations of graves\u2019 disease: an analysis in depth. J Thyroid Res. 2012;2012:768019. https:\/\/doi.org\/10.1155\/2012\/768019.","journal-title":"J Thyroid Res"},{"key":"4286_CR50","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000443828","volume":"5","author":"L Bartalena","year":"2016","unstructured":"Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C. The 2016 European thyroid association\/European group on graves\u2019 orbitopathy guidelines for the management of graves\u2019 orbitopathy. Eur Thyroid J. 2016;5:9\u201326. https:\/\/doi.org\/10.1159\/000443828.","journal-title":"Eur Thyroid J"},{"issue":"2","key":"4286_CR51","doi-asserted-by":"publisher","first-page":"CD010094","DOI":"10.1002\/14651858.CD010094.pub2","volume":"2016","author":"C Ma","year":"2016","unstructured":"Ma C, Xie J, Wang H, Li J, Chen S. Radioiodine therapy versus antithyroid medications for graves\u2019 disease. Cochrane Database Syst Rev. 2016;(2):CD010094. https:\/\/doi.org\/10.1002\/14651858.CD010094.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"4286_CR52","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12902-018-0322-7","volume":"18","author":"E Fanning","year":"2018","unstructured":"Fanning E, Inder WJ, Mackenzie E. Radioiodine treatment for graves\u2019 disease: a 10-year Australian cohort study. BMC Endocr Disord. 2018;18:94. https:\/\/doi.org\/10.1186\/s12902-018-0322-7.","journal-title":"BMC Endocr Disord"},{"key":"4286_CR53","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s40618-016-0484-y","volume":"39","author":"HX Li","year":"2016","unstructured":"Li HX, Xiang N, Hu WK, Jiao XL. Relation between therapy options for Graves\u2019 disease and the course of Graves\u2019 ophthalmopathy: a systematic review and meta-analysis. J Endocrinol Invest. 2016;39:1225\u201333. https:\/\/doi.org\/10.1007\/s40618-016-0484-y.","journal-title":"J Endocrinol Invest"},{"key":"4286_CR54","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1530\/EJE-07-0450","volume":"158","author":"P Laurberg","year":"2008","unstructured":"Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, T\u00f8rring O. TSH-receptor autoimmunity in graves\u2019 disease after therapy with antithyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol. 2008;158:69\u201375. https:\/\/doi.org\/10.1530\/EJE-07-0450.","journal-title":"Eur J Endocrinol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04286-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04286-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04286-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T14:48:30Z","timestamp":1759157310000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-04286-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4286"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04286-z","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of The Third Affiliated Hospital of Sun Yat-sen University ([2019]02-293-01) and was conducted in accordance with the principles outlined in the Declaration of Helsinki and in compliance with relevant laws and institutional guidelines. All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"676"}}